Clinical Trial Update: Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 3]

View source ↗

Summary

Phase 3 study comparing IBI354 to investigator's choice chemotherapy in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer; trial is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• IBI354

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Ovarian, Primary Peritoneal | Phase 3 | Status: RECRUITING